CINC - CinCor adds 13% as mid-stage trial for antihypertensive agent reaches main goal

CinCor Pharma ( NASDAQ: CINC ) shares climbed ~13% in the pre-market Monday after the cardio-renal drug developer said that its Phase 2 trial for lead asset baxdrostat met the primary endpoint in patients with treatment-resistant hypertension.

The company limited the enrollment of the BrigHtn trial to 275 patients per the advice of an Independent Data Review Committee which determined that the dose-ranging trial met the statistical criteria to show efficacy for baxdrostat at the highest dose.

The patients in the trial were under at least three antihypertensive agents at their maximally tolerated doses one of which was a diuretic.

According to topline data shared by CinCor ( CINC ), the candidate led to a statistically significant placebo-adjusted reduction in systolic blood pressure including a decline of 11 mmHg (p-value < 0.0001) at a dose of 2 mg.

After 12 weeks of therapy, the trial indicated no drug related serious adverse events or raised major safety concerns for all three dose cohorts.

The Treatment-Emergent SAEs seen in 10 patients were found to be unrelated to the study drug. The treatment-related adverse events including hyperkalemia and hypotension led to a discontinuation rate of less than 1% of (2 patients).

For further details see: